Skip to main content Accessibility help
×
Home

Authors' reply

  • Lena Palaniyappan (a1), Lisa Insole (a2) and Nicol Ferrier (a3)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Authors' reply
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Authors' reply
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Authors' reply
      Available formats
      ×

Abstract

Copyright

References

Hide All
Albers, LJ, Reist, C, Helmeste, D et al (1996) Paroxetine shifts imipramine metabolism. Psychiatry Research; 59: 189–96.
Alvan, G, Bechtel, P, Iselius, L et al (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. European Journal of Clinical Pharmacology; 39: 533–7.
Bitsios, P, Szabadi, E, Bradshaw, CM (1999) Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology; 143: 286–92.
Blier, P (2008) Resiliency of monoaminergic systems: the 80% rule and its relevance to drug development. Journal of Psychopharmacology; 22: 587–9.
Bymaster, FP, Dreshfield-Ahmad, LJ, Threlkeld, PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology; 25: 871–80.
Daws, LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacology and Therapeutics; 121: 8999.
Debonnel, G, Saint-André, É, Hébert, C et al (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology; 10: 5161.
Dodd, S, Horgan, D, Malhi, GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders; 89: 111.
Fava, M, Rosenbaum, JF, McGrath, PJ et al (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry; 151: 1372–4.
Fava, M, Alpert, J, Nierenberg, A et al (2002) Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. Journal of Clinical Psychopharmacology; 22: 379–87.
Harvey, AT, Rudolph, RL, Preskorn, SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry; 57: 503–9.
Ingelman-Sundberg, M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal; 5: 613.
Meyer, JH, Wilson, AA, Sagrati, S et al (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. American Journal of Psychiatry; 161: 826–35.
Nelson, JC, Mazure, CM, Bowers, MB et al (1991) A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry; 48: 303–7.
Nelson, JC, Mazure, CM, Jatlow, PI et al (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry; 55: 296300.
Owens, MJ, Krulewicz, S, Simon, JS et al (2008) Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology; 33: 3201–12.
Papakostas, G, Fava, M, Thase, M (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biological Psychiatry; 63: 699704.
Vaishnavi, SN, Nemeroff, CB, Plott, SJ et al (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biological Psychiatry; 55: 320–2.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Authors' reply

  • Lena Palaniyappan (a1), Lisa Insole (a2) and Nicol Ferrier (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *